Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223930 | 0.79 | MTNR1B (0.48) | MTNR1BPDGFRBENPP1KITKDR | |
| SCHEMBL1224202 | 0.76 | SIGMAR1 (0.43) | MTNR1BENPP1 | |
| SCHEMBL1223130 | 0.76 | SIGMAR1 (0.43) | MTNR1BENPP1 | |
| SCHEMBL1223131 | 0.76 | SIGMAR1 (0.43) | MTNR1BENPP1 | |
| SCHEMBL1224758 | 0.76 | MTNR1B (0.57) | MTNR1BPDGFRBENPP1KITKDR | |
| SCHEMBL1224756 | 0.76 | MTNR1B (0.57) | MTNR1BPDGFRBENPP1KITKDR | |
| SCHEMBL1148106 | 0.72 | SLC2A1 (0.51) | — | |
| SCHEMBL1147944 | 0.72 | SLC2A1 (0.51) | — | |
| SCHEMBL1148032 | 0.72 | SLC2A1 (0.51) | — | |
| SCHEMBL1147911 | 0.72 | TRPV1 (0.46) | MTNR1BMAOAMAOBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2905283-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-14 | — | — | EP | disclosed |
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | MTNR1B 321/4885PDGFRB 3961/4885ENPP1 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.